Zoracopan
Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB) [1].
Product Specifications
CAS Number
[2243483-63-6]
UNSPSC
12352005
Target
Complement System
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/zoracopan.html
Purity
99.85
Solubility
DMSO : ≥ 100 mg/mL
Smiles
C[C@]12[C@](C2)([H])N([C@@H](C1)C(NC3=C(C=CC(Br)=N3)C)=O)C(CN4C5=C(C)C=C(C6=CN=C(C)N=C6)C=C5C(C(C)=O)=C4)=O
Molecular Formula
C31H31BrN6O3
Molecular Weight
615.52
References & Citations
[1]Ocular drug depot for complement-mediated disorders. WO2021183555A1 - Ocular drug depot for complement-mediated disorders - Google Patents.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
DMWD, CT (DMWD, DM9, Dystrophia myotonica WD repeat-containing protein, Dystrophia myotonica-containing WD repeat motif protein, Protein 59, Protein DMR-N9) (FITC) discontinued
